rss
J Neurol Neurosurg Psychiatry 2008;79:978 doi:10.1136/jnnp.2008.152421
  • Editorial commentary

Treatment of neurocysticercosis: a randomised controlled trial

  1. Peter Odermatt1,
  2. Pierre-Marie Preux2,
  3. Michel Druet-Cabanac2
  1. 1
    Department of Public Health and Epidemiology, Swiss Tropical Institute, Basel, Switzerland
  2. 2
    University Limoges, Institut d’Epidémiologie neurologique et de Neurologie Tropicale (EA3174), Limoges, France
  1. Dr Pierre-Marie Preux, University Limoges, Institut d’Epidémiologie neurologique et de Neurologie Tropicale (EA3174), 2 rue du Dr Marcland, 87025 Limoges Cedex, France; preux{at}unilim.fr

    In this issue, Carpio and colleagues1 report on a randomised, double blind, placebo controlled trial on patients with neurocysticercosis (see page 1050). Their findings, published on behalf of the Ecuadorian Neurocysticercosis Group, add to the vividly debated issue of treatment of neurocysticercosis.2 Albendazole treatment was evaluated to reduce active brain cysts of neurocysticercosis and seizure recurrence. Carpio and colleagues1 found that in significantly more patients, active brain cysts were cured and a higher reduction of number of brain cysts was achieved. These findings confirm previous reports. However, although a significant reduction in brain cysts …

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    BMJ Careers - Latest neurology and neurosurgery jobs